Pregnancy Outcome in Women with Antiphospholipid Antibodies: Report on a Retrospective Study

 

 Permissions and Reprints

ABSTRACT

Antiphospholipid syndrome (APS) represents a serious risk factor in pregnancy resulting in several complications, leading to fetal loss and hemostatic complications. In this dedicated report, we describe our experiences in the treatment of pregnancies in patients with APS. The retrospective data from 140 pregnant women were investigated, and the treatment results of 121 patients were recorded. We studied two groups of patients receiving different treatment. The first group (n = 78) received the standard therapy with low-weight-molecular heparin (dalteparin 5000 U or certoparin 3000 U daily) and aspirin (100 mg daily) and in the second group (n = 43) an additional 0.2 g/kg intravenous immunoglobulin (IVIG). Outcomes were 74.3% and 83.7% live births in the first group and in the second group, respectively. The abortion rate was similar in both groups (11.5% vs. 11.6%). The late complication rate was lower in the second group (5.8% vs. 14.1%, p < 0.05) than in the group with standard therapy. Interestingly, we found a trend to higher percentage (> 12%) of natural killer (NK) cells in patients with pregnancy complications (60% vs. 12%, p < 0.05). Our retrospective data shows an improvement of late pregnancy complications by additional use of IVIG. It is possible that IVIG influences higher NK cell activity in patients with previous pregnancy complications.

REFERENCES

• 1 Birdsall M A, Lockwood G M, Ledger W L. Antiphospholipid antibodies in women having in-vitro fertilization.  Hum Reprod. 1996;  11 1185-1189
  PubMedGoogle Scholar
• 2 Carp H JA. Antiphospholipid syndrome in pregnancy.  Curr Opin Obstet Gynecol. 2004;  16 129-135
  CrossrefPubMedGoogle Scholar
• 3 Cervera R, Piette J C, Font J, Khamashta M A. for the Euro-Phospholipid project group . Antiphospholipid syndrome.  Arthritis Rheum. 2002;  46 1019-1027
  CrossrefPubMedGoogle Scholar
• 4 Katano K, Aoki A, Sasa H et al.. β 2-glykoprotein1-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women.  Hum Reprod. 1996;  11 509-512
  PubMedGoogle Scholar
• 5 Pattison N S, Chamley L W, McKay E J et al.. Antiphospholipid-antibodies in pregnancy: prevalence and clinical association.  Br J Obstet Gynaecol. 1993;  100 909-913
  PubMedGoogle Scholar
• 6 Schleussner E. Impact of the antiphospholipid syndrome on complications during pregnancy.  Transfus Med Hemother. 2006;  33 486-492
  CrossrefPubMedGoogle Scholar
• 7 Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy.  Obstet Gynecol. 1995;  86 555-559
  PubMedGoogle Scholar
• 8 Carp H JA. Intravenous immunoglobulin: effect on infertility and recurrent pregnancy loss.  Israel Medical Association Journal. 2007;  9 877-880
  PubMedGoogle Scholar
• 9 Clark D A, Coulam C B, Stricker R B. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and metaanalysis for patients who fail in vitro fertilization and embryo transfer(IVF).  J Assist Reprod Genet. 2006;  23 1-13
  PubMedGoogle Scholar
• 10 Canesi B, Brucato A. Antiphospholipid antibodies and pregnancy.  Haematologica Reports. 2005;  1 6-12
  PubMedGoogle Scholar
• 11 Galli M, Barbui T. Antiphospholipid antibodies and pregnancy.  Best Pract Res Clin Haematol. 2003;  16 211-225
  CrossrefPubMedGoogle Scholar
• 12 Salmon J E, de Groot P G. Pathogenic role of antiphospholipid antibodies.  Lupus. 2008;  17 405-411
  CrossrefPubMedGoogle Scholar
• 13 Kutteh W H. Antiphospholipid-antibody-associated recurrent pregnancy loss. Treatment with heparin and low dose aspirin is superior to low dose aspirin alone.  Am J Obstet Gynecol. 1996;  174 1584-1589
  CrossrefPubMedGoogle Scholar
• 14 Vashisht A, Regan L. Antiphospholipid syndrome in pregnancy—an update.  J R Coll Physicians (Edinburg). 2005;  35 337-339
  PubMedGoogle Scholar
• 15 Bates S M, Greer I A, Hirsh J, Ginsberg J S. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  127(suppl 3) 627-644
  PubMedGoogle Scholar
• 16 Empson M, Lassere M, Craig J C, Scott J R. Recurrent pregnancy loss with antiphospholipid antibody. A systematic review of therapeutic trials.  Obstet Gynecol. 2002;  99 135-144
  CrossrefPubMedGoogle Scholar
• 17 Stephenson M D, Ballem P J, Tsang P et al.. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular heparin to unfractionated heparin.  J Obstet Gynaecol Canada. 2004;  26 729-734
  PubMedGoogle Scholar
• 18 Branch W, Khamashta M A. Antiphospholipid syndrome: obstetric diagnosis. Management and controversies.  Obstet Gynecol. 2003;  101 1333-1344
  CrossrefPubMedGoogle Scholar
• 19 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update.  Thromb Haemost. 1995;  74 1185-1190
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Lim W, Crowther M A, Eikelboom J W. Management of antiphospholipid antibody syndrome: a systematic review.  JAMA. 2006;  295 1050-1057
  CrossrefPubMedGoogle Scholar
• 21 Lynch A M, Rutledge J H, Stephens J K et al.. Longitudinal measurement of anti-cardiolipin antibodies during normal pregnancy:a prospective study.  Lupus. 1995;  4 365-369
  CrossrefPubMedGoogle Scholar
• 22 Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphopsholipid syndrome in pregnancy and obstectrics: clinical characteristics, diagnosis, pathogenesis and treatment.  Semin Thromb Hemost. 2008;  34 267-273
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Pierangeli S S, Chen P P, Raschi E et al.. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.  Semin Thromb Hemost. 2008;  34 236-250
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Ogasawara M, Sasa H, Katano K et al.. Recurrent abortion and moderate or strong antiphospholipid antibody production.  Int J Gynaecol Obstet. 1998;  62 183-188
  CrossrefPubMedGoogle Scholar
• 25 Tincani A, Branch W, Levy R A et al.. Treatment of patients with antiphospholipid syndrome.  Lupus. 2003;  12 524-529
  CrossrefPubMedGoogle Scholar
• 26 Backos M, Rai R, Baxter N. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin.  Br J Obstet Gynaecol. 1999;  106 102-107
  PubMedGoogle Scholar
• 27 Cowchock S. Prevention of fetal death in the antiphospholipid antibody syndrome.  Lupus. 1996;  5 467-472
  PubMedGoogle Scholar
• 28 Clark A L, Branch D W, Silver R M. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy.  Obstet Gynecol. 1999;  93 437-441
  CrossrefPubMedGoogle Scholar
• 29 Alarcon-Segovia D, Boffa M C, Branch W et al.. Prophylaxis of the antiphospholipid syndrome: a consensus report.  Lupus. 2003;  12 499-503
  CrossrefPubMedGoogle Scholar
• 30 Greaves M, Cohen H, MacHin S J, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome.  Br J Haematol. 2000;  109 704-715
  CrossrefPubMedGoogle Scholar
• 31 Chang P, Millar D, Tsang P et al.. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report.  Am J Perinatol. 2006;  23 125-129
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Cowchock S. Treatment of antiphospholipid syndrome in pregnancy.  Lupus. 1998;  17 95-97
  PubMedGoogle Scholar
• 33 Farquharson R G, Jauniaux E, Exalto N. Updated and revised nomenclature for description of early pregnancy events.  Hum Reprod. 2005;  20 3008-3011
  CrossrefPubMedGoogle Scholar
• 34 Huong D LT, Wechsler B, Bletry O, Vaunthier-Brouzes D, Lefebvre G, Piette J-C. A study of 75 pregnancies in patients with antiphospholipid syndrome.  J Rheumatol. 2001;  28 2025-2030
  PubMedGoogle Scholar
• 35 Carp H JA, Asherson R A, Shoenfeld Y. Intravenous immunglobulin in pregnancies complicated by the antiphospholipid syndrome: what is its role.  J Clin Rheumatol. 2001;  7 291-294
  CrossrefPubMedGoogle Scholar
• 36 Perricone C, Carolis C D, Giacomelli R et al.. High levels of NK cells in the peripheral blood of patients affected with antiphospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis.  Rheumatology. 2007;  46 1574-1578
  CrossrefPubMedGoogle Scholar
• 37 Aoki K, Hayashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss.  Am J Reprod Immunol. 1993;  29 82-87
  PubMedGoogle Scholar
• 38 Emmer P M, Nelen W LDM, Steegers E AP, Hendriks J CM, Veerkoek M, Joosten I. Peripheral natural killer cell cytotoxicity and CD56pos CD16 pos cells increase during early pregnancy in women with a history of recurrent spontaneous abortion.  Hum Reprod. 2000;  15 1163-1169
  CrossrefPubMedGoogle Scholar
• 39 Van den Heuvel M J, Crystal G P, Hatta K, Han V K, Clark D A. Decline in number of elevated blood CD3+ CD56+ NKT cells in response to intravenous immunoglobulin treatment correlates with successful pregnancy.  Am J Reprod Immunol. 2007;  58 447-459
  CrossrefPubMedGoogle Scholar
• 40 Veenstra van Nieuwenhoven A L, Heinemann M J, Faas M M. The immunology of successful pregnancy.  Hum Reprod Update. 2003;  9 347-357
  CrossrefPubMedGoogle Scholar
• 41 Beer A E, Kwaak T Y, Ruiz J E. Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy loss and infertile women with multiple failed in vitro fertilization cycles.  Am J Reprod Immunol. 1996;  35 376-382
  PubMedGoogle Scholar
• 42 Coulam C B, Beaman K D. Reciprocal alteration in circulating TJ6+ CD19+ and TJ6+ CD56+ leukocytes in early pregnancy predict success or miscarriage.  Am J Reprod Immunol. 1995;  34 219-224
  PubMedGoogle Scholar
• 43 Kwak-Kim J, Gillman-Sachs A. Clinical implication of natural killer cells and reproduction.  Am J Reprod Immunol. 2008;  59 388-400
  CrossrefPubMedGoogle Scholar
• 44 Vila P, Hernandez M C, Lopez-Fernandez M F. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects.  Thromb Haemost. 1994;  72 209-213
  PubMedGoogle Scholar
• 45 Keskin D B, David S, Allan J et al.. TGFß promotes conversion of CD16+ peripheral blood NK cells into CD16-NK cells with similarities to decidual NK cells.  Proc Natl Acad Sci U S A. 2007;  104 3378-3383
  CrossrefPubMedGoogle Scholar
• 46 Sacks G, Fay L, Smith S, Russell P, Chapman M. NK cells analysis in women with recurrent reproductive failure; there is a clinical correlation between peripheral blood and endometrial biopsy samples.  The Royal Australian and New Zeeland College of Obstetricians and Gynecologists. 2007;  47(Suppl 1) A27-28
  PubMedGoogle Scholar
• 47 Varla-Leftherioti M, Spyropoulou-Vlachou M, Niokou D et al.. Natural killer (NK) cell receptors repertoire in couples with recurrent spontaneous abortions.  Am J Reprod Immunol. 2003;  49 183-191
  CrossrefPubMedGoogle Scholar
• 48 Varla-Leftherioti M, Spyropoulou-Vlachou M, Keramitsoglou T. Lack of the appropriate natural killer cell inhibitory receptors in women with spontaneous abortion.  Hum Immunol. 2005;  66 65-71
  PubMedGoogle Scholar
• 49 Wilson W A, Harris N. Management of antiphospholipid syndrome in pregnancy. In: Carp HJA Recurrent Pregnancy Loss. London, United Kingdom; Informa Healthcare 2007: 119-125
  Google Scholar
• 50 Vacca P, Pietra G, Falco M et al.. Analysis of natural killer cells isolated from human decidua: evidence that 2B4(CD244) functions as an inhibitory receptor and blocks NK-.cell function.  Blood. 2006;  108 4078-4085
  CrossrefPubMedGoogle Scholar
• 51 Yamada H, Shimada S, Kato E H et al.. Decrease in a specific killer cell immunoglobulin-like receptor on peripheral natural killer cells in women with recurrent spontaneous abortion of unexplained etiology.  Am J Reprod Immunol. 2004;  51 241-247
  CrossrefPubMedGoogle Scholar
• 52 Yamada H, Shimada S, Morikawa M et al.. Divergence of natural killer cell receptor and related molecule in the decidua from sporatic miscarriage with normal chromosome karyotype.  Mol Hum Reprod. 2005;  11 451-457
  CrossrefPubMedGoogle Scholar
• 53 Hiby S E, Regan L, Lo W, Farrell L, Carrington M, Moffet A. Association of maternal killer-cell immunoglobulin-like receptor and parental HLA-C genotypes with recurrent miscarriage.  Hum Reprod. 2008;  23 972-976
  CrossrefPubMedGoogle Scholar
• 54 Witt C S, Goodridge J, Gerbase-Delina M G, Daher S, Christiansen F T. Maternal KIR repertoire is not associated with recurrent spontaneous abortion.  Hum Reprod. 2004;  19 2653-2657
  CrossrefPubMedGoogle Scholar
• 55 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop.  Arthritis Rheum. 1999;  42 1309-1311
  CrossrefPubMedGoogle Scholar
• 56 Lockshin M D, Sammaritano L R, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome.  Arthritis Rheum. 2000;  43 440-443
  CrossrefPubMedGoogle Scholar
• 57 Bertolaccini M L, Khamashta M A. Laboratory diagnosis and management challenges in the antiphospholipid syndrome.  Lupus. 2006;  15 172-178
  CrossrefPubMedGoogle Scholar
• 58 Franklin R D, Hollier N, Kutteh W H. β2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss.  Fertil Steril. 2000;  73 531-535
  CrossrefPubMedGoogle Scholar
• 59 Carmo-Pereira S, Bertolaccini M L, Escudero-Contres A et al.. Value of IgA anticardiolipin and anti-B-2 glycoprotein 1 antibody testing in patients with pregnancy morbidity.  Ann Rheum Dis. 2003;  62 540-543
  CrossrefPubMedGoogle Scholar
• 60 Chong P, Matzner W, Ching W. Correlation between beta-2-glycoprotein antibodies and antiphospholipid antibodies in patients with reproductive failure.  Am J Reprod Immunol. 1998;  40 414-417
  PubMedGoogle Scholar
• 61 Kiprov D D, Nachtigall R D, Weavers R C, Jacobson A, Main E K, Garvoy M R. The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities.  Am J Reprod Immunol. 1996;  36 228-234
  CrossrefPubMedGoogle Scholar
• 62 Stojanovich L, Mikovic Z, Mandic V, Popvid-Kuzmanovic D. Treatment of antiphospholipid-syndrome in pregnancy with low dose of intravenous immunoglobulin.  Isr Med Assoc J. 2007;  9 555-556
  PubMedGoogle Scholar
• 63 Lynch A, Mariar R, Murphy J et al.. Antiphospholipid antibodies in predicting adverse pregnancy outcome.  Ann Intern Med. 1994;  120 470-475
  PubMedGoogle Scholar
• 64 Kaira S, Tuli A, Goyal U, Choudhary R, Raheja S. Correlation of antiphospholipid antibody IgM with first trimester recurrent abortion.  J Anat Soc India. 2002;  51 10-13
  PubMedGoogle Scholar
• 65 Lockwood C J, Omero R, Feinburg R F, Clyne L P, Coster B, Hobbins J C. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general population.  Am J Obstet Gynecol. 1989;  161 369-373
  PubMedGoogle Scholar
• 66 Fialova L, Mikolikova L, Matous-Malbohan I, Benesova O, Zwinger A. Prevalence of various antiphospholipid antibodies in pregnant women.  Physiol Res. 2000;  49 299-305
  PubMedGoogle Scholar
• 67 Branch D W, Andres R, Digre K B, Rote N S, Scott J R. The association of antiphospholipid antibodies with severe preeclampsia.  Obstet Gynecol. 1989;  73 541-545
  PubMedGoogle Scholar
• 68 Barbui T, Cortelazzo S, Galli M et al.. Antiphospholipid antibodies in early repeated abortions: a case-controlled study.  Fertil Steril. 1988;  50 589-592
  PubMedGoogle Scholar
• 69 Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients.  Lupus. 2003;  12 302-307
  CrossrefPubMedGoogle Scholar
• 70 Konova E, Ivanova I, Petrova P et al.. Effect of intravenous gamma-globulin therapy on lymphocyte population in pregnant women with antiphospholipid antibodies.  Akush Ginekol (Sofiia). 2004;  43 3-10
  PubMedGoogle Scholar
• 71 Branch D W, Peacman A M, Druzin M. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The pregnancy loss study group.  Am J Obstet Gynecol. 2000;  182 122-127
  CrossrefPubMedGoogle Scholar
• 72 Vaquero E, Lazzarin N, Valensise H. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low dose aspirin.  Am J Reprod Immunol. 2001;  45 174-179
  CrossrefPubMedGoogle Scholar
• 73 Valensise H, Vaquero E, de Carolis C. Normal fetal growth in women with antiphospholipid syndrome treated with high dose intravenous immunoglobulin (IVIG).  Prenat Diagn. 1995;  15 97-102
  CrossrefPubMedGoogle Scholar
• 74 Giannakopoulos B, Passam F, Rahgozar S, Krilis S A. Current concepts on the pathogenesis of the antiphospholipid syndrome.  Blood. 2007;  109 422-425
  CrossrefPubMedGoogle Scholar
• 75 Wang S, Zhao Y R, Jiao Y L et al.. Increased activating killer immunoglobulin-like receptor genes and decreased specific HLA-C alleles in couples with recurrent spontaneous abortion.  Biochem Biophys Res Commun. 2007;  360 696-701
  CrossrefPubMedGoogle Scholar
• 76 Caruso A D, Carolis S, Simone N. Antiphospholipid antibodies in obstetrics: new complexities and sites of action.  Hum Reprod. 1999;  5 267-276
  PubMedGoogle Scholar
• 77 Perricone C, Carolis C D, Giacomelli R et al.. High levels of NK cells in the peripheral blood of patients affected with antiphospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis.  Rheumatology. 2007;  46 1574-1578
  CrossrefPubMedGoogle Scholar
• 78 Sargent I L, Borzychowski A M, Redman C WG. NK cells and preeclampsia.  J Reprod Immunol. 2007;  76 40-44
  CrossrefPubMedGoogle Scholar
• 79 Radder C M, Roelen D L, van de Meer-Prind E M et al.. The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusion for fetal/alloimmune thrombozytopenia.  Am J Obstet Gynecol. 2004;  191 815-820
  CrossrefPubMedGoogle Scholar

Jawed FareedPh.D. 

Professor of Pathology & Pharmacology, Loyola University Medical Center

2160 S. First Avenue, Maywood, IL 60153

Email: jfareed@lumc.edu